The Patent Finder

TLC Biopharmaceuticals, Inc.

30 patents currently held · Updated Nov 21, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

3
Ending by 2030
May 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 16, 2027
    The maintenance fee for Pharmaceutical compositions to reduce complications of ocular steroid (US 10,350,294) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
  • 1 fee due Feb 27, 2027
    The maintenance fee for Pharmaceutical compositions of hydrophobic camptothecin derivatives (US 10,391,056) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
  • 3 fees due Apr 3 to 24, 2027 · next Apr 3
  • 1 fee due Sep 26, 2027
    The maintenance fee for Sustained-Release Anesthetic Compositions and Methods of Preparation Thereof (US 11,938,220) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,740,844Anti-VEGF monoclonal antibody
In force
 · USPTO record
In forceUSPTO record
US 8,956,600Ophthalmic drug delivery system containing phospholipid and cholesterol
In force
 · USPTO record
In forceUSPTO record
US 10,660,960Ophthalmic drug delivery system containing phospholipid and cholesterol
In force
 · USPTO record
In forceUSPTO record
US 9,987,360Ophthalmic drug delivery system containing phospholipid and cholesterol
In force
 · USPTO record
In forceUSPTO record
US 11,771,766Drug delivery system containing phospholipid and cholesterol
In force
 · USPTO record
In forceUSPTO record
US 10,058,616Pharmaceutical compositions to reduce complications of ocular steroid
In force
 · USPTO record
In forceUSPTO record
US 10,350,294Pharmaceutical compositions to reduce complications of ocular steroid
In force
 · USPTO record
In forceUSPTO record
US 10,391,056Pharmaceutical compositions of hydrophobic camptothecin derivatives
In force
 · USPTO record
In forceUSPTO record
US 9,789,062Methods of treating arthritis
In force
 · USPTO record
In forceUSPTO record
US 10,322,086Methods of Treating Arthritis
In force
 · Low confidence
In forceLow confidence
10 of 30 patents shown.
Pro members see all 30.
Pro members: see all 30 patents
Also on record, not counted in the 30: 1 patent in force now held by others · 4 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 6 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited